GLSI Greenwich LifeSciences, Inc.
USHealthcareAs of 2026-07-10 16:00
Why GLSI matters now
Greenwich LifeSciences, Inc. (GLSI) is a US stock in Healthcare. The latest InvestLog snapshot shows $19.80 with +1.18% on the session and $290.6M in market capitalization; recent performance reads 1-month -11.14% and YTD +11.28%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-5.7M, and EPS of $-0.39. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.7%.
The latest indexable market news headline is "Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $50.00; recent insider activity includes Patel Snehal filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
64.62
P/S
0.00
EV/EBITDA
-15.29
DCF Value
$-0.50
FCF Yield
-3.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-814.5%
ROA
-207.1%
ROIC
-415.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-5.7M | $-0.39 |
| Q4 2025 | $0.00 | $-7.9M | $-0.58 |
| FY 2025 | $0.00 | $-19.4M | $-1.43 |
| Q3 2025 | $0.00 | $-4.2M | $-0.30 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$50.00
Target (Median)
$50.00
Target Range
$50.00 - $50.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.38
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.